PAHO issues alert on extremely drug-resistant Shigella
The Pan American Health Organization (PAHO) this week issued an alert on the potential emergence and spread of extremely drug-resistant (XDR) Shigella sonnei in Latin America and the Caribbean.
Although to date cases of shigellosis caused by S sonnei have been reported only in countries with high surveillance capacity and high water, sanitation, and hygiene standards, the alert notes that cases of gastrointestinal infection caused by XDR S sonnei in men who have sex with men (MSM) have been rising in the United Kingdom and several other European countries. While shigellosis—one of the leading causes of severe infectious disease worldwide—is mainly caused by consumption of contaminated food and water, it can be transmitted through oral and anal sex and is considered a sexually transmitted disease.
Because millions of people in the Americas still lack access to clean drinking water and safe facilities for the disposal and elimination of feces, PAHO is concerned that if XDR S sonnei is introduced into the region in travelers returning from endemic areas, including MSM, there will be an increased risk of a major outbreak of diarrheal diseases that could be lethal in the main risk groups, including children under 5 years.
"Also of concern is the possible contribution of S. sonnei XDR to the spread of antibiotic resistance in the community through horizontal transfer of mobile genetic elements such as plasmids to other bacterial species," PAHO said.
Given this risk, PAHO is recommending that national authorities in the region strengthen surveillance and epidemiologic investigation of XDR S sonnei, strengthen the ability of clinical labs to identify and monitor resistance in S sonnei, continue efforts to provide access to safe water and adequate sanitation, boost infection prevention and control measures in healthcare settings, and work to prevent and minimize sexual transmission of the pathogen.
Jun 6 PAHO epidemiologic alert
Phage therapy shows promise in patients with non-TB Mycobacterium
Compassionate use of bacteriophage therapy in a small cohort of patients with antibiotic-resistant non-tuberculosis Mycobacterium (NTM) infections was well-tolerated and produced favorable responses in more than half, an international team of researchers reported today in Clinical Infectious Diseases.
For the study, a team led by researchers from the University of Pittsburgh and the University of California San Diego screened 200 isolates from patients with antibiotic-refractory NTM infections for susceptibility to bacteriophages. NTM infections, particularly those caused by Mycobacterium abscessus, are increasingly common among patients with cystic fibrosis and chronic bronchiectatic lung diseases and have become challenging to treat because of intrinsic antibiotic resistance. Based on two previous case reports of successful compassionate use of bacteriophages in NTM patients, the researcher wanted to further explore the potential.
Screening identified lytic phages for 55 isolates, and 20 patients who met the eligibility criteria were selected to receive personalized adjunctive phage therapy intravenously or by aerosolization. In 11 cases, only a single phage candidate was identified; in others, two or more phages were combined into a cocktail. The patients were monitored for adverse reactions, clinical and microbiologic responses, the emergence of phage resistance, and phage neutralization in serum, sputum, or bronchoalveolar lavage fluid.
No adverse reactions attributed to therapy were seen in any patient, and favorable clinical or microbiological responses were observed in 11 patients, with infections largely resolved in 5. Some patients, however, saw little clinical benefit. Neutralizing antibodies were identified in serum after initiation of phage delivery intravenously in 8 patients, potentially contributing to lack of treatment response in 4, but were not consistently associated with unfavorable responses in others. No phage resistance was observed in any of the 11 patients who received a single phage.
The study authors say further research into optimal routes of administration, dosage, pharmacodynamics, and tissue penetration is needed.
"This series of 20 patients treated with phages on a compassionate-use basis provides support for further evaluation of phages for treatment of mycobacterial infections," they wrote. "Although phage treatment of mycobacterial infections shows promise, this cohort illustrates some key limitations and lessons."
Jun 9 Clin Infect Dis abstract